Nivolumab
Nivolumab (brand name Opdivo) is a therapeutic monoclonal antibody used in cancer treatment — a fully human immunoglobulin G4 (IgG4) immune checkpoint inhibitor directed against Programmed cell death 1 (PD-1), a receptor expressed on the surface of activated T-lymphocytes.
Nivolumab (brand name Opdivo) is a therapeutic monoclonal antibody used in cancer treatment — a fully human immunoglobulin G4 (IgG4) immune checkpoint inhibitor directed against Programmed cell death 1 (PD-1), a receptor expressed on the surface of activated T-lymphocytes. Developed by Bristol-Myers Squibb and first approved by the FDA in 2014, it is administered intravenously and has since been approved across a broad range of malignancies, including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), hepatocellular carcinoma, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, bladder cancer, colorectal cancer, and classical Hodgkin lymphoma.
Mechanistically, nivolumab binds PD-1 and blocks its engagement by the ligands CD274 molecule and PD-L2, which tumor cells and cells of the tumor microenvironment express to deliver inhibitory signals to infiltrating T cells. Interrupting PD-1/PD-L1 signaling relieves this suppression and restores T-cell effector function, including interferon gamma production and cytotoxic killing of tumor cells, thereby countering a central mechanism of immune evasion. Because the same axis dampens T-cell activity in non-malignant settings, PD-1 blockade has also been explored experimentally for immunosuppressive states such as sepsis. In clinical oncology, nivolumab is given as monotherapy or in combination regimens: paired with the anti-CTLA-4 antibody ipilimumab for dual checkpoint blockade, in which PD-1 inhibition reinvigorates exhausted effector T cells while CTLA-4 inhibition promotes T-cell priming and expansion; with tyrosine kinase inhibitors such as cabozantinib in renal cell carcinoma; or alongside conventional chemotherapy. These combinations generally increase antitumor activity at the cost of more frequent immune-related adverse events, such as checkpoint inhibitor pneumonitis, colitis, and endocrinopathies. Candidate predictors of benefit — PD-L1 expression, tumor mutational burden, and microsatellite instability — are widely studied, but their reliability differs by tumor type, and mechanisms of primary and acquired resistance to PD-(L)1 blockade remain an active area of investigation.
Where the papers sit
44 papers from the last 6 months study nivolumab directly · updated from PubMed 16 Nov 2026
Study type 8 clinical trials · 20 observational · 7 human data · 4 preclinical · 5 unclassified
Themes 5 themes · 1 paradigm shift · 1 new direction
-
Nivolumab in Difficult Cancers
Nivolumab is being extended across cancer of unknown primary, mucosal melanoma, hepatocellular, urothelial, gastric, and other uncommon cancers. Combinations with lenvatinib, axitinib, chemotherapy, ipilimumab, and exosome vaccines seek to improve response beyond monotherapy. Real-world cohorts emphasize progression-free survival, objective response, feasibility, and treatment-related adverse events. Small trials, case series, and preclinical studies leave the best settings and biomarkers unresolved.
15 papers · 34.1%
-
Immune Checkpoint Toxicity and Resistance
Checkpoint blockade is being linked to tumor-immune remodeling, response biomarkers, and immune toxicity across solid tumors. Epigenetic priming, T-cell receptor features, and longitudinal microenvironment profiling are being used to explain response and resistance. Combinations with rucaparib, regorafenib, chemotherapy, and dual checkpoint blockade are expanding. Colitis, pneumonitis, and pancreatitis remain clinically important limits.
8 papers · 18.2%
-
Nivolumab in Lung Cancer
Nivolumab-based treatment is moving into neoadjuvant and adjuvant care for resectable non-small cell lung cancer. First-line combinations with ipilimumab, chemotherapy, vaccines, and galunisertib are being tested, including in PD-L1-low disease. Early detriment, treatment discontinuation, and real-world safety remain concerns alongside efficacy. COVID-19 vaccination and opioid use are emerging as contextual factors in outcomes.
8 papers · 18.2%
-
Immunotherapy in Renal Cancer
Renal cell carcinoma care is shifting toward first-line immunotherapy combinations and more deliberate sequencing after progression. Nivolumab with ipilimumab or cabozantinib is being assessed in clear-cell and non-clear-cell disease, while comparisons with pembrolizumab plus lenvatinib address regimen choice. Rechallenge and the timing of second-line nivolumab remain active clinical questions. Prognostic scores, cost-effectiveness, and real-world outcomes are shaping treatment selection.
7 papers · 15.9%
-
Nivolumab in Squamous Cancers
Nivolumab-based treatment is being applied across esophageal, oral, pharyngeal, laryngeal, and other squamous carcinomas. Real-world cohorts are defining effectiveness and safety for nivolumab alone or with ipilimumab, while probiotics and corticosteroid exposure may modify outcomes. CDK4/6 inhibition is being explored to expose subtype-specific immune vulnerabilities. Photoimmunotherapy offers a local-plus-systemic strategy, but its benefit remains supported mainly by early evidence.
6 papers · 13.6%
Nivolumab resistance is linked to suppressive myeloid remodeling, not simply inadequate T-cell activation
The advanced gastric cancer study and the metastatic castration-resistant prostate cancer biomarker study both challenge the assumption that nivolumab failure is explained primarily by insufficient antitumor T-cell activity. In gastric cancer, treatment increased antigen-reactive CD8+ T cells and reduced several immunosuppressive populations, yet progression was accompanied by re-expansion of activated regulatory T cells and emergence of APOC1+ lipid-associated macrophages; in prostate cancer, early progression despite nivolumab-containing therapy was associated with a TREM2-related myeloid gene signature replicated in independent datasets. Together, these findings shift the focus of resistance from checkpoint blockade alone toward the suppressive myeloid and stromal ecosystem that can reconstitute or persist during treatment, making that ecosystem a necessary target for explaining and overcoming resistance 42981428Nov 42873849Oct.
Infusion timing emerges as a potential chronotherapy variable for nivolumab
The second-line nivolumab study in metastatic renal cell carcinoma assigns the drug a role beyond disease selection, combination therapy, or biomarker-guided use by examining when each infusion is given. Patients receiving a greater proportion of infusions before noon had significantly longer progression-free and overall survival than those treated later in the day, suggesting that administration timing may become a modifiable component of nivolumab treatment rather than a purely logistical choice 42700745Sep.
Papers
The 44 papers from the last 6 months that study nivolumab directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Nivolumab in Difficult Cancers (15)
- Initial Clinical Experience With Gemcitabine, Cisplatin, and Nivolumab for Advanced Urothelial Carcinoma: A Four-case Series. In vivo (Athens, Greece) · 29 Oct 2026 PMID 42957262
- Real-World Outcomes of First-Line Nivolumab Monotherapy in Unfavorable Carcinoma of Unknown Primary: A Single-Center Retrospective Study. Journal of gastrointestinal cancer · 27 Oct 2026 PMID 42945001
- Efficacy and biomarker analysis for nivolumab in cancer of unknown primary: results from an investigator-initiated expanded access program. International journal of clinical oncology · 24 Sept 2026 PMID 42782574
- Flipped versus traditional nivolumab plus ipilimumab dosing in patients with melanoma brain metastases. European journal of cancer (Oxford, England : 1990) · 15 Sept 2026 PMID 42743884
- Association of Cachexia-Related Status With Treatment Outcomes in Advanced Gastric Cancer Receiving First-Line Therapy With or Without Nivolumab. Journal of gastrointestinal cancer · 11 Sept 2026 PMID 42726376
- Real-World Use of Adjuvant Nivolumab for Resected Stage III-IV Melanoma: 2-Year Analysis of AdjuMel. Dermatology and therapy · 29 Aug 2026 PMID 42667537
- Real-world Feasibility of Adjuvant Nivolumab for High-risk Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy. In vivo (Athens, Greece) · 28 Aug 2026 PMID 42665381
- Real-world safety and effectiveness of nivolumab in patients with cancer of unknown primary: results from a nationwide post-marketing surveillance in Japan. International journal of clinical oncology · 26 Aug 2026 PMID 42645637
- Phase II Trial of First-line Axitinib plus Nivolumab in Patients with Advanced Mucosal Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research · 13 Aug 2026 PMID 42594052
- Combination of exosome vaccines, lenvatinib, and anti-PD-1 eradicates tumor in autochthonous hepatocellular carcinoma mice. Cell reports. Medicine · 23 Jul 2026 PMID 42492521
- Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS). European journal of cancer (Oxford, England : 1990) · 29 Jun 2026 PMID 42372635
- Moxibustion combined with anti-PD-1 antibodies improves immunosuppression in septic mice potentially through the PD-1/PD-L1 pathway. Immunologic research · 17 Jun 2026 PMID 42307810
- Nivolumab in combination with lenvatinib in unresectable hepatocellular carcinoma: The IKF-t006/IMMUNIB translational phase-2 study. European journal of cancer (Oxford, England : 1990) · 12 Jun 2026 PMID 42284972
- Combos New and Old Counter PD-(L)1 Resistance, Treat Rare Cancers. Cancer discovery · 4 Jun 2026 PMID 42240229
- Temperature Dependent Motions of N-Terminal Loop in PD-1 Determine the Affinity Towards Nivolumab. Journal of molecular recognition : JMR · 27 May 2026 PMID 42199044
Immune Checkpoint Toxicity and Resistance (8)
- Longitudinal remodeling of the tumor-immune microenvironment during regorafenib, nivolumab, and chemotherapy in advanced gastric cancer. Science translational medicine · 4 Nov 2026 PMID 42981428
- Immune biomarkers of response and resistance to ipilimumab and nivolumab in metastatic castration-resistant prostate cancer. Science advances · 14 Oct 2026 PMID 42873849
- Analysis of a case of immune-related pancreatitis induced by anti-PD-1 antibody therapy for gastric cancer: A case report. Medicine · 9 Oct 2026 PMID 42854075
- Immune-related colitis following head and neck reconstructive surgery in a patient receiving long-term nivolumab. BMJ case reports · 6 Oct 2026 PMID 42838709
- Epigenetic Priming Sensitizes Metastatic Breast Cancer to Checkpoint Blockade by Rewiring the Tumor-Immune Microenvironment. Cancer research · 6 Oct 2026 PMID 42836774
- Complete response to dual immune checkpoint blockade in a patient with Birt-Hogg-Dubé syndrome and epithelioid angiomyolipoma. Journal for immunotherapy of cancer · 29 Jul 2026 PMID 42527032
- A Phase II Multicenter Trial of Rucaparib and Nivolumab as Maintenance Therapy in Patients with Advanced Biliary Tract Cancer: BilT-02. Clinical cancer research : an official journal of the American Association for Cancer Research · 23 Jul 2026 PMID 42489677
- Checkpoint Inhibitor Pneumonitis With Pneumomediastinum Following Nivolumab-AVD in Classic Hodgkin Lymphoma: A Case Report. Journal of pediatric hematology/oncology · 11 Jun 2026 PMID 42274365
Nivolumab in Lung Cancer (8)
- A phase II multi-institutional single arm trial evaluating TG4010 vaccine plus nivolumab in non-small cell lung cancer. Oncoimmunology · 2 Sept 2026 PMID 42684015
- Codelivery of nivolumab and galunisertib by EGFR-targeted spherical polymeric nanoparticles for effective treatment of non-small cell lung cancer. International journal of pharmaceutics · 26 Aug 2026 PMID 42648563
- Association between opioid use and treatment discontinuation in patients receiving nivolumab: a real-world database study. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 14 Aug 2026 PMID 42601535
- Nivolumab plus ipilimumab-based treatment in Japanese patients with metastatic non-small cell lung cancer and tumor PD-L1 < 1%: a pooled analysis. International journal of clinical oncology · 11 Aug 2026 PMID 42579028
- Impact of COVID-19 Vaccine Type on the Efficacy and Safety of Nivolumab in Patients With Metastatic Non-small-cell Lung Cancer: A Multicenter Study. In vivo (Athens, Greece) · 30 Jun 2026 PMID 42379805
- Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 26 Jun 2026 PMID 42360104
- Neoadjuvant nivolumab plus chemotherapy in resectable NSCLC: A pharmacological outcome study. Pakistan journal of pharmaceutical sciences · 9 Jun 2026 PMID 42262212
- Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial. JAMA · 1 Jun 2026 PMID 42224490
Immunotherapy in Renal Cancer (7)
- Timing of Second-Line Nivolumab and Survival in Metastatic Renal Cell Carcinoma. Clinical genitourinary cancer · 5 Sept 2026 PMID 42700745
- Cost‑effectiveness of first‑line immunotherapy-based combination regimens for advanced renal cell carcinoma in China and the United States. Human vaccines & immunotherapeutics · 22 Aug 2026 PMID 42630013
- Real-World Outcomes and Prognostic Factors of Immune Checkpoint Inhibitor Rechallenge for Metastatic Renal Cell Carcinoma: A Multicenter Study. International journal of urology : official journal of the Japanese Urological Association · 1 Jul 2026 PMID 42385189
- Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study. Oncoimmunology · 29 Jun 2026 PMID 42366526
- Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review. European journal of cancer (Oxford, England : 1990) · 3 Jun 2026 PMID 42235464
- Comparison of effectiveness and safety of pembrolizumab plus lenvatinib versus nivolumab plus cabozantinib for metastatic renal cell carcinoma: a real-world study. International journal of clinical oncology · 27 May 2026 PMID 42204034
- Three-factor Clinical Score for First-line Nivolumab Plus Ipilimumab in Metastatic Renal Cell Carcinoma. Anticancer research · 27 May 2026 PMID 42203341
Nivolumab in Squamous Cancers (6)
- Real-World Outcomes of Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Oral Cavity, Pharynx, and Larynx: An Australian Population-Based Study. Head & neck · 14 Nov 2026 PMID 43032914
- Bivariate Copula Models With Event-Free Cure Effect for Survival Extrapolations and Individual-Level Correlation Analysis. Statistics in medicine · 29 Oct 2026 PMID 42952322
- Abscopal-like Regression of Lung Metastases After Near-infrared Photoimmunotherapy Plus Nivolumab in Laryngeal Carcinoma. Anticancer research · 27 Oct 2026 PMID 42946420
- Real-world outcomes of ipilimumab plus nivolumab in esophageal squamous cell carcinoma: a multi-institutional large cohort study. Cancer immunology, immunotherapy : CII · 14 Jun 2026 PMID 42289036
- CDK4/6 inhibition uncovers subtype-specific vulnerabilities and immune-related responses in esophageal squamous cell carcinoma. Cell death & disease · 29 May 2026 PMID 42215475
- Association of Probiotics with Effectiveness of Nivolumab or Pembrolizumab in Patients with Esophageal Cancer Taking Proton Pump Inhibitors: A Multicenter Retrospective Study. Journal of gastrointestinal cancer · 25 May 2026 PMID 42183961
By study type
Clinical trials (8)
- Longitudinal remodeling of the tumor-immune microenvironment during regorafenib, nivolumab, and chemotherapy in advanced gastric cancer. Science translational medicine · 4 Nov 2026 PMID 42981428
- A phase II multi-institutional single arm trial evaluating TG4010 vaccine plus nivolumab in non-small cell lung cancer. Oncoimmunology · 2 Sept 2026 PMID 42684015
- Phase II Trial of First-line Axitinib plus Nivolumab in Patients with Advanced Mucosal Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research · 13 Aug 2026 PMID 42594052
- A Phase II Multicenter Trial of Rucaparib and Nivolumab as Maintenance Therapy in Patients with Advanced Biliary Tract Cancer: BilT-02. Clinical cancer research : an official journal of the American Association for Cancer Research · 23 Jul 2026 PMID 42489677
- Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 26 Jun 2026 PMID 42360104
- Nivolumab in combination with lenvatinib in unresectable hepatocellular carcinoma: The IKF-t006/IMMUNIB translational phase-2 study. European journal of cancer (Oxford, England : 1990) · 12 Jun 2026 PMID 42284972
- Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review. European journal of cancer (Oxford, England : 1990) · 3 Jun 2026 PMID 42235464
- Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial. JAMA · 1 Jun 2026 PMID 42224490
Observational studies and case reports (20)
- Initial Clinical Experience With Gemcitabine, Cisplatin, and Nivolumab for Advanced Urothelial Carcinoma: A Four-case Series. In vivo (Athens, Greece) · 29 Oct 2026 PMID 42957262
- Abscopal-like Regression of Lung Metastases After Near-infrared Photoimmunotherapy Plus Nivolumab in Laryngeal Carcinoma. Anticancer research · 27 Oct 2026 PMID 42946420
- Real-World Outcomes of First-Line Nivolumab Monotherapy in Unfavorable Carcinoma of Unknown Primary: A Single-Center Retrospective Study. Journal of gastrointestinal cancer · 27 Oct 2026 PMID 42945001
- Analysis of a case of immune-related pancreatitis induced by anti-PD-1 antibody therapy for gastric cancer: A case report. Medicine · 9 Oct 2026 PMID 42854075
- Immune-related colitis following head and neck reconstructive surgery in a patient receiving long-term nivolumab. BMJ case reports · 6 Oct 2026 PMID 42838709
- Flipped versus traditional nivolumab plus ipilimumab dosing in patients with melanoma brain metastases. European journal of cancer (Oxford, England : 1990) · 15 Sept 2026 PMID 42743884
- Association of Cachexia-Related Status With Treatment Outcomes in Advanced Gastric Cancer Receiving First-Line Therapy With or Without Nivolumab. Journal of gastrointestinal cancer · 11 Sept 2026 PMID 42726376
- Timing of Second-Line Nivolumab and Survival in Metastatic Renal Cell Carcinoma. Clinical genitourinary cancer · 5 Sept 2026 PMID 42700745
- Real-world Feasibility of Adjuvant Nivolumab for High-risk Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy. In vivo (Athens, Greece) · 28 Aug 2026 PMID 42665381
- Association between opioid use and treatment discontinuation in patients receiving nivolumab: a real-world database study. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 14 Aug 2026 PMID 42601535
- Complete response to dual immune checkpoint blockade in a patient with Birt-Hogg-Dubé syndrome and epithelioid angiomyolipoma. Journal for immunotherapy of cancer · 29 Jul 2026 PMID 42527032
- Real-World Outcomes and Prognostic Factors of Immune Checkpoint Inhibitor Rechallenge for Metastatic Renal Cell Carcinoma: A Multicenter Study. International journal of urology : official journal of the Japanese Urological Association · 1 Jul 2026 PMID 42385189
- Impact of COVID-19 Vaccine Type on the Efficacy and Safety of Nivolumab in Patients With Metastatic Non-small-cell Lung Cancer: A Multicenter Study. In vivo (Athens, Greece) · 30 Jun 2026 PMID 42379805
- Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS). European journal of cancer (Oxford, England : 1990) · 29 Jun 2026 PMID 42372635
- Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study. Oncoimmunology · 29 Jun 2026 PMID 42366526
- Checkpoint Inhibitor Pneumonitis With Pneumomediastinum Following Nivolumab-AVD in Classic Hodgkin Lymphoma: A Case Report. Journal of pediatric hematology/oncology · 11 Jun 2026 PMID 42274365
- Neoadjuvant nivolumab plus chemotherapy in resectable NSCLC: A pharmacological outcome study. Pakistan journal of pharmaceutical sciences · 9 Jun 2026 PMID 42262212
- Comparison of effectiveness and safety of pembrolizumab plus lenvatinib versus nivolumab plus cabozantinib for metastatic renal cell carcinoma: a real-world study. International journal of clinical oncology · 27 May 2026 PMID 42204034
- Three-factor Clinical Score for First-line Nivolumab Plus Ipilimumab in Metastatic Renal Cell Carcinoma. Anticancer research · 27 May 2026 PMID 42203341
- Association of Probiotics with Effectiveness of Nivolumab or Pembrolizumab in Patients with Esophageal Cancer Taking Proton Pump Inhibitors: A Multicenter Retrospective Study. Journal of gastrointestinal cancer · 25 May 2026 PMID 42183961
Human data, design not indexed (7)
- Bivariate Copula Models With Event-Free Cure Effect for Survival Extrapolations and Individual-Level Correlation Analysis. Statistics in medicine · 29 Oct 2026 PMID 42952322
- Immune biomarkers of response and resistance to ipilimumab and nivolumab in metastatic castration-resistant prostate cancer. Science advances · 14 Oct 2026 PMID 42873849
- Efficacy and biomarker analysis for nivolumab in cancer of unknown primary: results from an investigator-initiated expanded access program. International journal of clinical oncology · 24 Sept 2026 PMID 42782574
- Cost‑effectiveness of first‑line immunotherapy-based combination regimens for advanced renal cell carcinoma in China and the United States. Human vaccines & immunotherapeutics · 22 Aug 2026 PMID 42630013
- Nivolumab plus ipilimumab-based treatment in Japanese patients with metastatic non-small cell lung cancer and tumor PD-L1 < 1%: a pooled analysis. International journal of clinical oncology · 11 Aug 2026 PMID 42579028
- Combos New and Old Counter PD-(L)1 Resistance, Treat Rare Cancers. Cancer discovery · 4 Jun 2026 PMID 42240229
- Temperature Dependent Motions of N-Terminal Loop in PD-1 Determine the Affinity Towards Nivolumab. Journal of molecular recognition : JMR · 27 May 2026 PMID 42199044
Preclinical: animal, cell and lab studies (4)
- Epigenetic Priming Sensitizes Metastatic Breast Cancer to Checkpoint Blockade by Rewiring the Tumor-Immune Microenvironment. Cancer research · 6 Oct 2026 PMID 42836774
- Codelivery of nivolumab and galunisertib by EGFR-targeted spherical polymeric nanoparticles for effective treatment of non-small cell lung cancer. International journal of pharmaceutics · 26 Aug 2026 PMID 42648563
- Combination of exosome vaccines, lenvatinib, and anti-PD-1 eradicates tumor in autochthonous hepatocellular carcinoma mice. Cell reports. Medicine · 23 Jul 2026 PMID 42492521
- Moxibustion combined with anti-PD-1 antibodies improves immunosuppression in septic mice potentially through the PD-1/PD-L1 pathway. Immunologic research · 17 Jun 2026 PMID 42307810
Unclassified: not yet indexed with MeSH (5)
- Real-World Outcomes of Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Oral Cavity, Pharynx, and Larynx: An Australian Population-Based Study. Head & neck · 14 Nov 2026 PMID 43032914
- Real-World Use of Adjuvant Nivolumab for Resected Stage III-IV Melanoma: 2-Year Analysis of AdjuMel. Dermatology and therapy · 29 Aug 2026 PMID 42667537
- Real-world safety and effectiveness of nivolumab in patients with cancer of unknown primary: results from a nationwide post-marketing surveillance in Japan. International journal of clinical oncology · 26 Aug 2026 PMID 42645637
- Real-world outcomes of ipilimumab plus nivolumab in esophageal squamous cell carcinoma: a multi-institutional large cohort study. Cancer immunology, immunotherapy : CII · 14 Jun 2026 PMID 42289036
- CDK4/6 inhibition uncovers subtype-specific vulnerabilities and immune-related responses in esophageal squamous cell carcinoma. Cell death & disease · 29 May 2026 PMID 42215475
Written from 44 PubMed abstracts, each one listed by PMID above. Published: 2026-06-16. Last written: 2026-09-13 by GPT. Reviewed by a human editor on 2026-07-23. Drafted by language models from published abstracts; not medical advice.